KROMATID Launches KROMASURE(TM) PinPoint: Next Generation, High-Throughput Transgene Integration Analysis

Revolutionary Single-Cell Platform Delivers Unprecedented Resolution for Genomic Insight—Gene Edited Therapy Development

BOULDER, Colo., May 27, 2025 /PRNewswire/ -- KROMATID, a leader in structural genomics innovation, is proud to announce the release of an expanded capability for its Advanced Cytogenetics Platform. KROMASURE^™ PinPoint provides a proprietary high-throughput solution designed to redefine the standards of transgene genomic integration analysis. With single-cell resolution and unmatched sensitivity, PinPoint empowers researchers to detect integration events as small as 2kb—with the ability to screen up to 1,000 individual cells in a single experiment.

Optimized for Cell and Gene Therapy development, PinPoint delivers precise, quantitative insight into transgene insertional copy number and modal distribution on a single-cell basis, enabling the identification of low-prevalence events that are typically missed by pooled assays. This sets a new benchmark for supporting regulatory compliance and risk profiling in gene therapy and cell line development.

"PinPoint is not just a product—it's a transformation in how we visualize and understand transgene insertion," said Erin Cross, VP of Platform at KROMATID. "With its high-resolution, interphase-capable design, PinPoint meets the growing demand for rigorous, scalable, and compliant genomic analysis—even in non-dividing cells where traditional metaphase-based methods fall short."

A New Approach to Advance Transgene Integration Analysis

While sequencing and ddPCR have long been the standards for assessing insertional copy number, they are limited by their reliance on pooled cell populations—obscuring the cell-to-cell variability that is critical for accurate characterization. By analyzing individual cells, developers can now detect small targets, visualize rare integration patterns, and understand the true distribution of copy number across a population.

"We're now able to visualize and profile transgene integrations in thousands of single cells," said Cross. "This expanded capability gives developers a clearer picture of how their editing machinery performs at the cellular level, helping them understand transgene distribution with far greater precision than pooled average measurements can provide."

Advanced Data Insights

• Precise Chromosomal Mapping: Pinpoints exact integration loci down to individual chromosomes
• Single-Cell High-Throughput Analysis: Enables profiling of up to 1,000 cells per run to capture rare, low-prevalence events
• Risk Profiling and Compliance Support: Facilitates data-driven safety and regulatory assessments
• Interphase Visualization: Detects integrations in non-dividing cells, expanding the scope of analysis beyond traditional cytogenetics
• Integrated Data Interpretation: Seamlessly integrates with KROMASURE^™ InSite for orthogonal validation and comprehensive genomic insight

About KROMATID
KROMATID is a contract research organization (CRO) specializing in cytogenetic precision, empowering the cell and gene therapy community with advanced genomic integrity analysis solutions. Through our cutting-edge KROMASURE^™ platform, we provide high-confidence, single-cell insights into chromosomal integrity, -filling critical gaps left by traditional sequencing methods. Our cytogenetic platform helps biotech, pharma, CDMOs, and academic researchers accelerate breakthroughs, ensure regulatory confidence, and drive innovation in genomic medicine. With a commitment to data-driven innovation, transparency, and continuous improvement, KROMATID is revolutionizing human medicine-seeing is believing.

For media inquiries please contact:
Amanda Ladas
Global Marketing Manager
773-720-0709
[email protected]
www.kromatid.com

SOURCE KROMATID